Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)

Bullboard Posts

Comment by Jefferam1on Mar 15, 2017 1:52pm

178 Views

Post# 25983335

RE:New article on CEO Dan Legault and Antibe

I just read the CEO article and sounds very promissing.
Nothing really new other then simply repeating the same points.
But it's very encourging that management have a VERY clear direction and are pushing hard to accomplish it.
200 people in the first Phase 2 trial starting in spring then 250 in the second phase 2 trial starting in fall with results expected by Q2/2018
Strategy is to partner with big pharma prior to Phase 3 test which is a 2 year test.
We can expect that partnership is where the stock price will sky rocket (if it hasn't started before then).

Bullboard Posts

Debt-free cannabis company set for next stage of growth